Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025)
Aytu Biopharma's (AYTU) quarterly Cash from Investing Activities came in at -$17000.0 in Q4 2025, down 111.72% year-over-year from $145000.0 in Q4 2024, and up 99.44% quarter-over-quarter from -$3.0 million in Q2 2025.
Powered by 
Analysis
Aytu Biopharma (AYTU) Cash from Investing Activities (2015 - 2025) Analysis & Trends
Aytu Biopharma (AYTU) has reported Cash from Investing Activities for 11 consecutive years, with -$17000.0 the latest figure, recorded in Q4 2025.
- On a quarterly basis, Cash from Investing Activities fell 111.72% year-over-year to -$17000.0 in Q4 2025; TTM through Mar 2026 was -$3.0 million, a 817.26% decrease from a year earlier, with the FY2025 full-year figure at -$2.6 million, down 678.12% from the prior year.
- Cash from Investing Activities was -$17000.0 for Q4 2025 at Aytu Biopharma, up from -$3.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $381000.0 in Q3 2024 and troughed at -$3.1 million in Q4 2021.
- A 5-year average of -$483166.7 and a median of -$57000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities plunged 10070.0% in 2021 and jumped 601.32% in 2024, its largest moves.
- Over 5 years, Cash from Investing Activities stood at -$3.1 million in 2021, then soared by 99.84% to -$5000.0 in 2022, then tumbled by 3380.0% to -$174000.0 in 2023, then surged by 183.33% to $145000.0 in 2024, then tumbled by 111.72% to -$17000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$17000.0 (Q4 2025), -$3.0 million (Q2 2025), and -$69000.0 (Q1 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -1.11 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | -1.20 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -5.60 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -3.11 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.11 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -424.26 Mn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | -1.66 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -51.79 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 87.50 Mn |
| 10 | Aytu Biopharma | 22.49 Mn | -4.22 Mn | 7.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -17,000.00 |
| Jun 30, 2025 | -3.02 Mn |
| Mar 31, 2025 | -69,000.00 |
| Dec 31, 2024 | 145,000.00 |
| Sep 30, 2024 | 381,000.00 |
| Jun 30, 2024 | -34,000.00 |
| Mar 31, 2024 | -45,000.00 |
| Dec 31, 2023 | -174,000.00 |
| Sep 30, 2023 | -76,000.00 |
| Jun 30, 2023 | -155,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2022 | -5,000.00 |
| Sep 30, 2022 | 42,000.00 |
| Jun 30, 2022 | -41,000.00 |
| Mar 31, 2022 | -70,000.00 |
| Dec 31, 2021 | -3.05 Mn |
| Sep 30, 2021 | -86,000.00 |
| Jun 30, 2021 | -2.43 Mn |
| Dec 31, 2020 | -30,000.00 |
| Sep 30, 2020 | -9,000.00 |